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TUMOUR specific transplantation antigens have been detected in carcinogen-
induced tumours by demonstrating that prior exposure of syngeneic hosts to
tumour cells, which are prevented from progressive growth, induces resistance
against a subsequent tumour cell inoculum. The majority ofstudies so far, have
been conducted with sarcomata and epitheliomata induced with polycyclic
hydrocarbon carcinogens in the mouse (Prehn, 1965; Sj6gren, 1965) and to a
lesser extent in rats and guinea-pigs (Baldwin, 1955; Morton, Goldman and
Wood, 1965). Neoplasms induced with chemical carcinogens other than poly-
cyclic hydrocarbons have not received as much attention but Baldwin and Barker
(1967) have shown that 4-dimethylaminoazobenzene (DMAB)-induced rat hepa-
tomata possess tumour specific antigens.
Immunity to carcinogen-induced tumours is specifically mediated by imuno-
logically competent cells andresistance can be passivelytransferred withlymphoid
cells, including lymph node cells, thoracic duct lymphocytes and peritoneal
exudate cells from immune donors. In contrast, serum from immune donors has
not produced consistent effects on the growth of tumour cells in syngeneic hosts.
Thus, treatment in some cases caused enhancement of tumour growth, in others
slight resistance was obtained whilst in many cases it was without effect (Bubenik
and Koldovsky, 1964; M6ller, 1964). Furthermore, whilst cytotoxicity tests
have been effective for demonstrating humoral antibody in hosts immunized
against viral-induced leukaemias (Old and Boyse, 1965) such procedures have not
been so successful in studies with larger carcinoma orsarcoma cells. This has been
ascribed to the low concentration of tumour antigens on the tumour cell surface,
rendering the cell insensitive to cytotoxic antibody (Klein, 1966).
The present communication describes experiments designed to detect humoral
antibody in serum from rats immunized with transplanted rat hepatomata,
originally induced with 4-dimethylaminoazobenzene, by the influence of serum
on the growth of tumour inocula in syngeneic rats and by the application of the
indirect fluorescent antibody test.
MATERIALS AND METHODS
Inbred rats of the Wistar and Slonaker strains were used for all experiments.
These were kept on a standard cubed diet (MRC 41B) with water ad tibitum.
* Present address: The Department of Medicine, University of Cambridge.
33R. W. BALDWIN AND C. R. BARKER
Hepatoma induction
Wistar rats of both sexes and initially 2-3 months old were fed a low protein
diet containing 0-06 per cent 4-dimethylaminoazobenzene (DMAB) for three
months (Baldwin, 1964). Thereafter they were kept on the basal diet until liver
tumours became palpable. Healthy non-necrotic tumours were passaged subcu-
taneously in rats of the same sex as the donor so as to avoid immune reactions
against sex-determined antigens. Details of the histology of these tumours has
been reported (Baldwin, 1964), the majority being classified as hepatocellular
carcinomata.
Induction of immunity to transplanted hepatomata
Resistance to transplanted hepatomata was induced in syngeneic hosts either
by repeated implantation of tumour grafts prevented from progressive growth
by exposure to 60Co y-irradiation (15,000 R.) or by surgical excision of tumour
grafts when they attained a size of approximately 1 cm. in average diameter
(Baldwin and Barker, 1967). The degree of immunity was determined by chal-
lenge of the treated rats with viable tumour cell suspensions and this immunity
was maintained by re-challenges with 5 x 105 viable tumour cells at 4 to 6 week
intervals. Tumour cell suspensions were prepared as described previously
(Baldwin, 1966) by repeatedly stirring finely minced tumour in 0-25 per cent
trypsin (1 x cryst., Seravac Laboratories, Maidenhead) containing a few drops of
0-02 per cent deoxyribonuclease (1 x cryst.; Sigma Chemical Co., St. Louis, Mo.,
U.S.A.). Cell viability was assessed by the trypan blue exclusion test.
Blood samples were collected at stages during immunization either by cardiac
puncture under ether anaesthesia or by tail bleeding, and the serum stored at
-20° C. Each sample was collected between 7 and 21 days following a challenge
with either irradiated tumour or viable tumour cells.
Isoantisera
Slonaker-anti-Wistar serum was prepared by implanting viable grafts of D23
hepatoma by trocar into male Slonaker rats initially 10 weeks old. Between 5 and
11 grafts wereimplanted at 2 to 4weeklyintervals andbloodsampleswere collected
by cardiac puncture from 7 to 21 days after implantations. Serum was collected
and stored at -20° C.
Indirect fluorescent antibody test
The indirect fluorescent antibody test was performed on suspensions of living
cells essentially as described by Moller (1961) for the demonstration of mouse
isoantigens. Tumour cells liberated from finely minced tumour by trypsinization
as described earlier were resuspended in 20 per cent calfserum in medium 199 and
collected by centrifugation (30 x g for 3 minutes). The cells were washed twice
in medium 199 and finally resuspended at a concentration of approximately
107 cells/ml. in this medium. Between 4 and 7 x 106 cells were sedimented by
gentle centrifugation (30 x g for 3 minutes), the supernatant was replaced with
0 1 ml. ofrat antiserum and incubated at 370 for 20 minutes. The cells were then
washed three times with medium 199 by centrifugation and incubated for 20
minutes at 370 C. with 0*1 ml. of undiluted fluorescein isothiocyanate conjugated
rabbit anti-rat globulin (Microbiological Associates, Bethesda, U.S.A.). The cells
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were then washed twice in medium 199 before resuspension in 0 3 ml. of 1: 1 v/v
glycerol: isotonic phosphate saline (pH 7.3). The final cell suspension was
stored at 0° C. until examined (within 24 hours) with a Reichert fluorescence
microscope under dark ground illumination. All tests included controls ofnormal
rat serum, serum from rats immunized to the target tumour cell and a Slonaker
anti-Wistar isoimmune serum as a positive control. Cells exhibiting complete
ring staining of the cell membrane or of isolated points on the membrane were
scored as positive. As described by Moller (1961) diffuse fluorescence of the cell
indicates death ofthe cell and such stained cells were omitted from the test. The
proportion of fluorescent stained cells was calculated from examination of 100 to
200 cells. Fluorescence indices were calculated as the proportion ofnegative cells
in the sample exposed to normal rat serum minus the proportion of negative cells
in the sample exposed to the test serum, divided by the former figure.
Effect of serum on tumour growth
The effect ofa single dose ofserum from immune rats was tested by incubating
viable tumour cells, liberated by trypsinization, with the test serum for 30 minutes
at room temperature before inoculating syngeneic rats subcutaneously with the
mixture. Where the effect of multiple doses was tested, subsequent doses of
serum were administered intraperitoneally at 3 to 4 day intervals. In controls
tumour cells were treated with either normal rat serum or serum from rats immune
to a different hepatoma.
RESULTS
Demonstration of humoral antibody by the indirect fluorescent antibody test
Positive fluorescence indices were obtained in all the indirect fluorescent anti-
bodytests utilizing target cells from sixtransplanted hepatomataoriginallyinduced
in Wistar rats with 4-dimethylaminoazobenzene and a series ofsera from syngeneic
rats immunized against individual tumours (Table I). In most cases, only weak
staining was obtained and a large proportion of the positively stained cells exhi-
bited fluorescent point staining ofthe cell membrane rather than complete fluores-
cent rings. The percentage of dead cells showing general fluorescence of the
cytoplasm was generally less than 5 per cent. The fluorescence indices were
usually ofa low order ranging from values of0-19 to a maximum of0 55with serum
1581 against D23 tumour cells. In contrast much higher fluorescence indices
(0.54 to 0.81) were obtained with isoantisera produced by repeated implantation
of tumour D23 into Slonaker rats (Table II). The fluorescent staining was also
more intense with the isoantiserum, a highproportion ofthe positive cells exhibited
complete ring reactions.
There was no marked difference in the humoral antibody response evoked by
either implantation ofheavily irradiated tumour or excision ofdeveloping tumour
grafts. Moreover repeated rejection ofviable tumour challenges did not markedly
enhance antibody levels. For example with tumour D33 there was no marked
difference in the fluorescence indices in sera obtained between the 6th and 12th
challenge. Immuno-fluorescent staining was also observed with the sera of rats
which had been passively immunized with peritoneal exudate cells from immune
donors and had resisted a series of subsequent challenges with viable cells.
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TABLE I.-Indirect Fluorescent Antibody Tests with Viable Cell Suspensions of
DMAB-Induced Hepatomnata and Immune Sera
Treatment ofserum donors
Serum
number
1581
1672
1487
1362
1341
1475
1489
1580
1476
1605
1681
1412
1430
1445
1462
1453
1478
1479
1486
Immunizing
tumourand
source of
target cells
D23/17-25*
D23/18-25
D23/16-26
D30/5-6
D30/2-4
D30/5-20
D31/7-17
D31/7-20
D31/1-17
D33/5-19
D33/9-19
D33/3-8
D33/3-8
D33/3-9
D33/3-10
D43/1-2
D43/5-6
D43/5-6
D43/3-8
1499 . D44/3-9
1671 . D44/3-16
Immunizationt
3 x IR
3 x IR
3 x IR
3 x IR
3 x IR
3 x IR
Passive transfer
Passive transfer
3 x IR
3 x IR
3 x IR
3 x IR
3 x IR
3 x IR
3 x IR
3 x IR
Excision
Excision
3 x IR
3 x IR
3 x IR
No. of
challenges
with viable
cells Fluorescence
(5 x 105) indices
4 . 0-39, 0-55
6 . 0-35, 0-40
8 .047
- . 0*19, 0*21
2 . 0-31, 027, 040
11 . 0*25, 0*32, 0-37
8 .0*33
10 . 0*44, 0*50
16 . 0*43, 0*22
6 .0*41
7 .042
8 .0*35
9 .0-36
10 . 0*51, 0-38, 0'25
12 . 0*39, 0-26
2 .0*50
2 .041
2 .0*32
5 . 0*46, 0-30, 0-43
0*27, 0*40, 0*38
3 .0*51
8 . 0-32, 0*40
* Transfer generations of tumour used in the course of immunization and
challenges with viable cells.
t IR-Implantation of 60Co y-irradiated tumour grafts. Excision-
Surgical excision of growing tumour grafts. Passive transfer-Immunity
transferred to normal syngeneic rats by means of peritoneal exudate cells
from immune donors (Baldwin and Barker, 1967).
TABLE II.-Indirect Fluorescent Antibody Staining of Tumour-Immune Antisera
with Different DMAB-Induced Hepatoma Cells
Serum from rats
immune to tumours
D23 .
D30
D31
D33
D43
D44 .
Slonaker isoantiserum*
Fluorescence indices against target cells
from tumours
t A
I
D23
0 47
0*13
0-03
0*06
0*07
0*05
0*75
D30
0
0*29
0*06
0-02
-0*08
-0*01
0 75
D31
0*05
0 03
0-38
0-02
0*04
0*05
0.80
D33
0
-0*01
0.01
0 40
0 04
0*01
0-76
D43
-0*01
0*08
0*05
0*01
0-41
0*05
0*81
* Slonaker rats immunized against Wistar D23 hepatoma.
Specificity of the fluorescent antibody test for individual tumours
To test the specificity of the indirect fluorescent antibody test, sera from rats
immunized against one hepatoma were tested against each ofthe other 5 DMAB-
induced hepatomata. The results, summarized in Table II, indicate that, apart
from one test with D23 tumour, antisera only showed positive staining with cells
D44
0
-0 04
-0-08
0X01
-0-06
0*37
0 54
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ofthe immunizing tumour. In many cases sera gave negative indices with other
hepatoma cells when the degree of interaction was less than the non-specific
interaction between normal rat serum and the cells. Pooled antiserum from
rats immune to tumour D30 showed positive staining with cells of this tumour
(fluorescence index, 0.29) and also reacted weakly with D23 cells (fluorescence
index, 0.13). The significance of this latter reaction is doubtful however since
only indices of above 0x20 are considered positive. Apart from this particular
test, indices of between 0-08 and -0-08 were obtained in tests when sera were
reacted with cells from tumours other than the immunizing tumour.
The specificity of the serum antibody to individual tumours was also demon-
strated by absorption studies (Table III). Thus incubation of D23-immune
TABLE 1II.-Effect of Absorption with Viable Hepatoma Cells on the Indirect
Fluorescent Antibody Test
Target cells
in indirect
Tumour cells fluorescent
Serum immune used for antibody Fluorescence
to tumour absorption* test index
0 40
23 D23 -0 11
{ D33 }D23{ 0-40
r -) f 0 42
D33 D23 D33 041
D33 0 01
* 2 x 108 viable tumour cells/ml. of immune serum.
serum with D23 cells (2 x 108 cells/ml. serum) at 0° C. for one hour absorbed the
antibody so that the serum no longer showed positive staining with this tumour
(fluorescence index, -0.11). However, treatment ofthe serum with an equivalent
number ofD33 tumour cells did not modify the activity ofthe serum towards D23
tumour. Thus fluorescence indices of 0 40 were obtained with both unabsorbed
and D33-absorbed antiserum against D23 cells. Likewise, antibody in D33-
immune serum could be effectively removed by absorption with D33 tumour cells
(2 x 108/ml. serum), whilst D23 tumour cells were without effect.
Effect of serumfrom tumour-immune rats on growth of transplanted hepatomata
In two tests, incubation oftumour D23 cells with D23 immune serum (0.5 ml.
and 0-4 ml.) markedly enhanced growth ofthe tumour in syngeneic rats compared
with controls treated with normal rat serum (Table IV). This was reflected by a
shorter latent period and an enhanced growth rate ofD23 tumour cells treatedwith
the anti-D23 tumour antiserum. Thus the mean tumour diameters at 28 days in
rats treated with the tumour-specific antiserum were significantly greater than
those in normal serum treated controls (P < 0-001 and 0 05 in Experiments 1 and
2). In another experiment (Experiment 3) where D23 tumour cells were mixed
with a smaller volume ofantiserum (0.1 ml.) and further 0 1 ml. doses ofantiserum
were administered intraperitoneally at 3- to 4-day intervals, the effect was not so
pronounced, but again treatment with anti-D23 tumour antiserum enhanced
tumour growth compared to the effect of serum from rats immunized against D43
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TABLE IV.-Influence on Tumour Growth in Syngeneic Recipients of Antisera
against Tumour-specific Antigens in DMAB-induced Rat Hepatomata
Treatment
Serum donors of Tumour
immune to recipients* takes
1 D23/8 20 D23
Normal
2 D23/20 5 D23
Normal
3 D23/20 5 D23
D43
4 D31/11 20 D31
D30
5 D33/9 20 D33
D39
6 D33/11 5 D33
Normal
7 D33/11 20 D33
D33
D23
1 x 0 5 ml.
I x0S5 ml.
I x 0-4 ml.
I x 0-4 ml.
5xO-l ml.
5x 0-1 ml.
I x 0-2 ml.
I x 0-2 ml.
I x 0-2 ml.
I x 0-2 ml.
I x 04 ml.
I xO04 ml.
5xO-l ml.
5 x 0-02 ml.
5xO-l ml.
3/4
4/4
4/4
4/4
4/4
4/4
4/4
4/4
4/4
4/4
3/4
3/4
4/4
4/4
4/4
Mean tumour diameter
(cm.) after (days)
14 21 28
1-3 3 0 4-6
0X2 0-8 10
1.1 2-8 4.4
0 4 1-2 2-6
1-7 3.3 4-4
1-3 2X4 3X2
0*9 1X6 2-6
0-2 1.0 1.5
1-4 3*0 4 0
1-5 2-6 3.7
0.9 18 3-0
0-5 1.1 2-5
0 1.5 2-9
1-1 2-0 3-1
0 1-i 2-0
* Where a single treatment was given, serum and tumour cells were mixed in vitro.
tumour. This reflected in the increased mean tumour diameter at day 28 in the
D23-antiserum treated group (P < 0.005).
In tests with D31 tumour cells, a single treatment with anti-D31 tumour anti-
serum (0.2 ml.) did not enhance tumour growth significantly as compared with the
effect of antiserum from rats immune to another hepatoma. Similarly in two
tests (Experiments 5 and 6) a single treatment of D33 tumour cells with 0-2 ml.
and 0-4 ml. of anti-D33 tumour antiserum did not significantly influence the rate
of tumour growth when compared with controls treated with normal rat serum.
In a third test (Experiment 7) D33 tumour cells were initially treated with 0-1 ml.
or 0-02 ml. ofanti-D33 tumour antiserum before inoculation into normal syngeneic
recipients and afurther fourintraperitoneal injections of serum (0.1 ml. or 0-02 ml.)
were administered at 3-4 day intervals. Control rats received D33 tumour cells
similarly treated with 0-1 ml. doses of anti-D23 tumour serum. Under these
conditions there was enhanced growth of the D33 tumour cells treated with the
two doses of anti-D33 tumour antiserum. This is reflected by the increases in
mean tumour diameters in the groups treated with 0-1 ml. or 0-02 ml. aliquots of
anti-D33 tumour antiserum (P < 0-05 and 0.02).
DISCUSSION
Previous studies (Baldwin and Barker, 1967) showed that DMAB-induced rat
hepatomata were moderately antigenic and resistance could be induced in syn-
geneic hosts so that challenges with up to 106 cells were rejected. This resistance
was mediated by immunologically competent cells and could be passively trans-
ferred with peritoneal exudate cells from immune donors. The present findings
show that humoral antibody, directed against tumour specific antigens on the cell
surface, is also present in the immunized rats. This antibody could be detected
Tumour
and
Experi- transfer
ment generation
Challenge
dose
(cells x 104)
798TUMOUR-SPECIFIC HUMORAL ANTIBODY
in vitro by the indirect fluorescent antibody test and also byits effect onthe growth
of tumour cells transplanted to syngeneic recipients. The tumours were all of
recent origin, the majority ofthe tests being performed within the first 20 genera-
tions of transfer of the tumour, whilst several experiments were performed within
the first 6 generations, thereby excluding the possibility ofisoantigenic differences
resulting from repeated transplantation.
Positive fluorescent staining reactions were demonstrated with each hepatoma
studied using antisera prepared by immunizing syngeneic hosts. The staining
reactions were relatively weak, fluorescence indices of between 0419 and 0-55 being
obtained. This contrasts with the stronger reactions observed with Moloney
and Graffi virus induced mouse tumours (Klein and Klein, 1964; Pasternak, 1965)
whilst Lejneva, Zilber and Ievleva (1965), obtained indices of up to 0-78 follow-
ing staining of 3-methylcholanthrene-induced sarcomata cells with sera from mice
hyperimmunized with irradiated grafts ofthese tumours.
Within the limited group of hepatomata studied, the antibody response was
found to be specific for individual tumours and there was no conclusive evidence
of cross-reactions. This lack of cross-reactivity between hepatomata cells indi-
cates that the antibody is directed against cell surface antigens which are specific
to individual tumours.
Efforts to demonstrate humoral antibody against DMAB-induced rat hepa-
tomata by other in vitro procedures have been uniformly unsuccessful. Thus, the
cytotoxicity test, which has provided a sensitive method for detecting tumour
antigens in viral-induced leukaemic cells (Old and Boyse, 1965), was consistently
negative. These observations are comparable to those obtained in other studies
with sarcoma and carcinoma cells (Old et al., 1962) and, it has been suggested, may
reflect the low concentration of tumour antigen on the cell surface (Klein, 1966).
Furthermore, attempts to demonstrate precipitating antibody against a variety
ofhepatoma extracts, including tumour sonicates, deoxycholate solubilized micro-
somes, cell sap and a soluble S5 extract (Hirai et al., 1963) have been negative.
These observations contrast with a recent report of Hirai (1965) which recorded
the demonstration of an isoprecipitin in the serum ofrats immune to a strain ofthe
Yoshida hepatoma which reacted with a soluble tumour antigen.
Humoral antibody in tumour-immune serum was also demonstrated by its
enhancing effect on the growth of treated hepatoma cells in syngeneic recipients
(Table IV). The degree of enhancement produced by the antihepatoma anti-
serum was, in some cases, comparable to thatpreviouslyreported against 3-methyl-
cholanthrene-induced sarcomata (Bubenik and Koldovsky, 1964; M6ller, 1964).
However, the influence of tumour-immune sera on the hepatomata was not so
consistent since, in some examples, treatment did not significantly modify tumour
growth. Furthermore, low doses of serum did not inhibit growth oftransplanted
hepatomata as observed with methylcholanthrene-induced mouse sarcomata
(Bubenik and Koldovsky, 1964). These observations also reflect the low antibody
response evoked in syngeneic hosts by DMAB-induced hepatomata.
Whether the humoral antibody response and the tumour specific transplanta-
tion resistance (Baldwin and Barker, 1967) are evoked bythesameantigensremains
to be determined. In both cases, however, present evidence indicates that the
immune response to hepatoma cells is specific for individual tumours.
The humoral antibody response to hepatoma cells, as measured by the indirect
fluorescent antibody staining and the serum transfer test was low compared with
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that demonstrated with 3-methylcholanthrene-induced mouse sarcomata (Lejneva
et al., 1965; Bubenik and Koldovsky, 1964). Likewise, the degree of trans-
plantation resistance inducible to hepatoma cells was less than that evoked against
the mouse sarcomata (Klein et al., 1960; Old et al., 1962). These observations
suggest that the concentration of tumour specific antigens on the hepatoma cells
is low compared to polycyclic hydrocarbon-induced sarcomata.
The development of a reliable in vitro procedure for demonstrating humoral
antibody to hepatoma cell antigens provides a practicable test for a more extensive
search for common, tumour specific antigens in this tumour type and also will
make possible investigations into the nature of these cell surface antigens.
SUMMARY
1. Humoral antibody against tumour-specific antigens in 4-dimethylamino-
azobenzene (DMAB)-induced rat hepatomata has been demonstrated in vitro
by application of the indirect fluorescent antibody test. Using this technique
it was demonstrated, both by direct staining, and by absorption methods that the
antigens were characteristic for individual hepatomata.
2. Humoral antibody was also demonstrable in vivo by its enhancing effect
on the growth of hepatoma cells transplanted into syngeneic recipients. The
influence of tumour specific antisera was not as pronounced as that demon-
strated with polycyclic hydrocarbon-induced mouse sarcomas and this possibly
reflects the weaker antigenicity of DMAB-induced hepatoma cells.
This investigation was supported by a block grant from the British Empire
Cancer Campaign for Research.
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